$25.33
0.251.00%
At Close: -
$25.45
0.120.47%
After Hours: 7:49 PM EDT
15 minutes delayed
Comments
Loading...
Intellia Therapeutics
NTLANASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Intellia Therapeutics (NASDAQ:NTLA) Stock, Analyst Ratings, Price Targets, Forecasts
Intellia Therapeutics Inc has a consensus price target of $97 based on the ratings of 33 analysts. The high is $252 issued by Goldman Sachs on August 6, 2021. The low is $29 issued by Citigroup on May 10, 2024. The 3 most-recent analyst ratings were released by Canaccord Genuity, Cantor Fitzgerald, and Truist Securities on June 27, 2024, June 24, 2024, and June 24, 2024, respectively. With an average price target of $86 between Canaccord Genuity, Cantor Fitzgerald, and Truist Securities, there's an implied 237.92% upside for Intellia Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Cantor Fitzgerald
Truist Securities
Citigroup
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Intellia Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 186.84% | Canaccord Genuity | Whitney Ijem | $73 → $73 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 155.4% | Cantor Fitzgerald | Rick Bienkowski | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 371.52% | Truist Securities | Joon Lee | $120 → $120 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 155.4% | Cantor Fitzgerald | Rick Bienkowski | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2024 | Buy Now | 155.4% | Cantor Fitzgerald | Rick Bienkowski | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 13.95% | Citigroup | David Lebowitz | $31 → $29 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 175.05% | BMO Capital | Kostas Biliouris | $62 → $70 | Maintains | Outperform | Get Alert |
| 04/23/2024 | Buy Now | 13.95% | Wedbush | David Nierengarten | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 25.74% | Goldman Sachs | Salveen Richter | → $32 | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 186.84% | Canaccord Genuity | Whitney Ijem | $72 → $73 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 11/13/2023 | Buy Now | 175.05% | Oppenheimer | Jay Olson | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/13/2023 | Buy Now | 233.99% | Morgan Stanley | Terence Flynn | $90 → $85 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 143.62% | BMO Capital | Kostas Biliouris | $64 → $62 | Maintains | Outperform | Get Alert |
| 11/10/2023 | Buy Now | 175.05% | RBC Capital | Luca Issi | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/10/2023 | Buy Now | 434.39% | Goldman Sachs | Salveen Richter | $157 → $136 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 123.97% | Raymond James | Steven Seedhouse | $78 → $57 | Maintains | Outperform | Get Alert |
| 09/13/2023 | Buy Now | 155.4% | Cantor Fitzgerald | Rick Bienkowski | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 155.4% | Cantor Fitzgerald | Rick Bienkowski | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 155.4% | Cantor Fitzgerald | Rick Bienkowski | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | Buy Now | 253.64% | Barclays | Gena Wang | $86 → $90 | Maintains | Overweight | Get Alert |
| 08/07/2023 | Buy Now | 155.4% | Canaccord Genuity | Whitney Ijem | $66 → $65 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | 320.44% | Chardan Capital | Geulah Livshits | → $107 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 253.64% | Barclays | Gena Wang | $148 → $90 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 57.17% | Citigroup | David Lewis | $44 → $40 | Maintains | Neutral | Get Alert |
| 06/13/2023 | Buy Now | 257.57% | B of A Securities | Greg Harrison | $89 → $91 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 320.44% | Chardan Capital | Geulah Livshits | $111 → $107 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 198.63% | Credit Suisse | Richard Law | → $76 | Reiterates | Outperform → Outperform | Get Alert |
| 05/08/2023 | Buy Now | 72.89% | Citigroup | David Lewis | $39 → $44 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 253.64% | Oppenheimer | Jay Olson | $93 → $90 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | 237.92% | Morgan Stanley | Terence Flynn | $83 → $86 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 151.48% | BMO Capital | Kostas Biliouris | $57 → $64 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 206.49% | Raymond James | Steven Seedhouse | $94 → $78 | Maintains | Outperform | Get Alert |
| 04/13/2023 | Buy Now | 159.33% | Canaccord Genuity | Whitney Ijem | → $66 | Initiates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | 210.42% | JP Morgan | Brian Cheng | $82 → $79 | Maintains | Overweight | Get Alert |
| 03/21/2023 | Buy Now | 112.18% | Bernstein | William Pickering | → $54 | Initiates | → Outperform | Get Alert |
| 03/14/2023 | Buy Now | 123.97% | BMO Capital | Kostas Biliouris | $54 → $57 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/27/2023 | Buy Now | 336.15% | Chardan Capital | Geulah Livshits | $129 → $111 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 198.63% | Credit Suisse | Richard Law | $88 → $76 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 265.43% | Oppenheimer | Jay Olson | $115 → $93 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 65.03% | Baird | Jack Allen | $58 → $42 | Maintains | Neutral | Get Alert |
| 02/24/2023 | Buy Now | 355.8% | EF Hutton | Michael King | $123 → $116 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 269.35% | Raymond James | Steven Seedhouse | $124 → $94 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 163.26% | Cantor Fitzgerald | Rick Bienkowski | → $67 | Initiates | → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 53.24% | Citigroup | David Lebowitz | $48 → $39 | Upgrade | Sell → Neutral | Get Alert |
| 01/23/2023 | Buy Now | 230.06% | SVB Leerink | Mani Foroohar | $86 → $84 | Maintains | Outperform | Get Alert |
| 01/19/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 01/04/2023 | Buy Now | 371.52% | Wells Fargo | Yanan Zhu | $135 → $120 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 245.78% | Credit Suisse | Richard Law | $109 → $88 | Maintains | Outperform | Get Alert |
| 12/02/2022 | Buy Now | 237.92% | SVB Leerink | Mani Foroohar | $90 → $86 | Maintains | Outperform | Get Alert |
| 11/15/2022 | Buy Now | 406.88% | Chardan Capital | Geulah Livshits | $121 → $129 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 383.3% | EF Hutton | Michael King | $130 → $123 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 226.13% | Morgan Stanley | Terence Flynn | $84 → $83 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 387.23% | Raymond James | Steven Seedhouse | $127 → $124 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 328.29% | Credit Suisse | Richard Law | $101 → $109 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 375.45% | Chardan Capital | Geulah Livshits | $146 → $121 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 410.81% | EF Hutton | Michael King | → $130 | Initiates | → Buy | Get Alert |
| 10/11/2022 | Buy Now | 230.06% | Morgan Stanley | Terence Flynn | → $84 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | Buy Now | 233.99% | JP Morgan | Brian Cheng | → $85 | Initiates | → Overweight | Get Alert |
| 09/19/2022 | Buy Now | 336.15% | JMP Securities | Silvan Tuerkcan | $106 → $111 | Maintains | Market Outperform | Get Alert |
| 09/19/2022 | Buy Now | 520.83% | SVB Leerink | Mani Foroohar | $152 → $158 | Maintains | Outperform | Get Alert |
| 09/01/2022 | Buy Now | 96.47% | Citigroup | David Lebowitz | → $50 | Initiates | → Sell | Get Alert |
| 08/05/2022 | Buy Now | 497.25% | SVB Leerink | Mani Foroohar | $155 → $152 | Maintains | Outperform | Get Alert |
| 08/05/2022 | Buy Now | 473.68% | Chardan Capital | Geulah Livshits | $172 → $146 | Maintains | Buy | Get Alert |
| 06/17/2022 | Buy Now | 112.18% | BMO Capital | Kostas Biliouris | → $54 | Initiates | → Market Perform | Get Alert |
| 06/16/2022 | Buy Now | 175.05% | B of A Securities | Greg Harrison | → $70 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 607.27% | Goldman Sachs | Salveen Richter | $206 → $180 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 410.81% | Oppenheimer | Jay Olson | $160 → $130 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 332.22% | JMP Securities | Silvan Tuerkcan | $165 → $110 | Maintains | Market Outperform | Get Alert |
| 05/06/2022 | Buy Now | 285.07% | Credit Suisse | Richard Law | $100 → $98 | Maintains | Outperform | Get Alert |
| 05/06/2022 | Buy Now | 312.58% | Raymond James | Steven Seedhouse | $181 → $105 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | 292.93% | Credit Suisse | Richard Law | → $100 | Initiates | → Outperform | Get Alert |
| 03/07/2022 | Buy Now | 257.57% | Brookline Capital | — | → $91 | Upgrade | Hold → Buy | Get Alert |
| 03/01/2022 | Buy Now | 575.84% | Chardan Capital | Geulah Livshits | $177 → $172 | Maintains | Buy | Get Alert |
| 02/18/2022 | Buy Now | — | William Blair | Raju Prasad | — | Initiates | → Outperform | Get Alert |
| 02/14/2022 | Buy Now | — | Brookline Capital | — | — | Initiates | → Hold | Get Alert |
| 02/07/2022 | Buy Now | 489.4% | Oppenheimer | Jay Olson | $145 → $150 | Upgrade | Perform → Outperform | Get Alert |
| 01/31/2022 | Buy Now | — | Cowen & Co. | Joseph Thome | — | Initiates | → Outperform | Get Alert |
| 01/07/2022 | Buy Now | 571.91% | Piper Sandler | Swapnil Malekar | → $171 | Initiates | → Overweight | Get Alert |
| 01/07/2022 | Buy Now | 548.34% | JMP Securities | Silvan Tuerkcan | $175 → $165 | Maintains | Market Outperform | Get Alert |
| 11/05/2021 | Buy Now | 469.75% | Oppenheimer | Jay Olson | — | Maintains | Perform | Get Alert |
| 11/05/2021 | Buy Now | 615.13% | HC Wainwright & Co. | Michael King | — | Maintains | Buy | Get Alert |
| 10/05/2021 | Buy Now | 567.98% | Guggenheim | Debjit Chattopadhyay | — | Initiates | → Buy | Get Alert |
| 09/24/2021 | Buy Now | 579.77% | Stifel | Dae Gon Ha | — | Initiates | → Buy | Get Alert |
| 08/06/2021 | Buy Now | 611.2% | Raymond James | Steven Seedhouse | — | Maintains | Outperform | Get Alert |
| 08/06/2021 | Buy Now | 587.63% | JMP Securities | — | — | Maintains | Market Outperform | Get Alert |
| 08/06/2021 | Buy Now | 528.69% | Oppenheimer | Jay Olson | — | Maintains | Perform | Get Alert |
| 08/06/2021 | Buy Now | 890.18% | Goldman Sachs | — | — | Maintains | Buy | Get Alert |
| 08/06/2021 | Buy Now | 595.49% | Chardan Capital | Geulah Livshits | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Intellia Therapeutics (NTLA) stock?
The latest price target for Intellia Therapeutics (NASDAQ:NTLA) was reported by Canaccord Genuity on June 27, 2024. The analyst firm set a price target for $73.00 expecting NTLA to rise to within 12 months (a possible 186.84% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intellia Therapeutics (NTLA)?
The latest analyst rating for Intellia Therapeutics (NASDAQ:NTLA) was provided by Canaccord Genuity, and Intellia Therapeutics maintained their buy rating.
When was the last upgrade for Intellia Therapeutics (NTLA)?
The last upgrade for Intellia Therapeutics Inc happened on March 14, 2023 when BMO Capital raised their price target to $57. BMO Capital previously had a market perform for Intellia Therapeutics Inc.
When was the last downgrade for Intellia Therapeutics (NTLA)?
The last downgrade for Intellia Therapeutics Inc happened on February 23, 2024 when Goldman Sachs changed their price target from N/A to $32 for Intellia Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Intellia Therapeutics (NTLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Intellia Therapeutics (NTLA) correct?
While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a maintained with a price target of $73.00 to $73.00. The current price Intellia Therapeutics (NTLA) is trading at is $25.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.